In several other studies, FXR activation was observed to improve glucose metabolism, reverse insulin resistance and enhance insulin sensitivity, which in turn highlighted the potential of FXR agonists (i.e., bile acids and their synthetic derivatives) as therapies for metabolic syndrome, diabetes and obesity [9,10,11,12]. This evidence concerns the gene NR1H4 and obesity disorder.